| # | Title | Journal | Year | Citations |
|---|
| 1 | Catalog of 5’ Fusion Partners in ALK-positive NSCLC Circa 2020 | JTO Clinical and Research Reports | 2020 | 62 |
| 2 | Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042 | JTO Clinical and Research Reports | 2021 | 32 |
| 3 | The Role of Interleukin 1β in the Pathogenesis of Lung Cancer | JTO Clinical and Research Reports | 2020 | 27 |
| 4 | EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors | JTO Clinical and Research Reports | 2020 | 26 |
| 5 | Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC | JTO Clinical and Research Reports | 2020 | 23 |
| 6 | Efficacy of Taletrectinib (AB-106/DS-6051b) in ROS1+ NSCLC: An Updated Pooled Analysis of U.S. and Japan Phase 1 Studies | JTO Clinical and Research Reports | 2021 | 20 |
| 7 | Ultrarapid EGFR Mutation Screening Followed by Comprehensive Next-Generation Sequencing: A Feasible, Informative Approach for Lung Carcinoma Cytology Specimens With a High Success Rate | JTO Clinical and Research Reports | 2020 | 18 |
| 8 | Catalog of 5′ fusion partners in RET+ NSCLC Circa 2020 | JTO Clinical and Research Reports | 2020 | 17 |
| 9 | A Systematic Review and Meta-Analysis of Clinical Characteristics and Outcomes in Patients With Lung Cancer with Coronavirus Disease 2019 | JTO Clinical and Research Reports | 2021 | 16 |
| 10 | Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in BAP1 Gene | JTO Clinical and Research Reports | 2021 | 16 |
| 11 | Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations | JTO Clinical and Research Reports | 2021 | 15 |
| 12 | A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC | JTO Clinical and Research Reports | 2022 | 15 |
| 13 | Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC | JTO Clinical and Research Reports | 2022 | 15 |
| 14 | Severe Immune Checkpoint Inhibitor Hepatitis in KRAS G12C-Mutant NSCLC Potentially Triggered by Sotorasib: Case Report | JTO Clinical and Research Reports | 2021 | 14 |
| 15 | A Real-World Evaluation of Atezolizumab Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC in Canada | JTO Clinical and Research Reports | 2021 | 14 |
| 16 | Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1–Deficient Mesothelioma: Safety, Efficacy, and Resistance Mechanisms | JTO Clinical and Research Reports | 2020 | 14 |
| 17 | Implementing Lung Cancer Screening in Europe: Taking a Systems Approach | JTO Clinical and Research Reports | 2022 | 14 |
| 18 | Preclinical Characterization of Mobocertinib Highlights the Putative Therapeutic Window of This Novel EGFR Inhibitor to EGFR Exon 20 Insertion Mutations | JTO Clinical and Research Reports | 2021 | 13 |
| 19 | Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous Non‒Small-Cell Lung Cancer in KEYNOTE-407 | JTO Clinical and Research Reports | 2021 | 13 |
| 20 | Important Surgical and Clinical End Points in Neoadjuvant Immunotherapy Trials in Resectable NSCLC | JTO Clinical and Research Reports | 2021 | 13 |
| 21 | Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC | JTO Clinical and Research Reports | 2022 | 13 |
| 22 | A Novel Sequentially Evolved EML4-ALK Variant 3 G1202R/S1206Y Double Mutation In Cis Confers Resistance to Lorlatinib: A Brief Report and Literature Review | JTO Clinical and Research Reports | 2021 | 12 |
| 23 | A Real-World Analysis of the Use of Systemic Therapy in Malignant Pleural Mesothelioma and the Differential Impacts on Overall Survival by Practice Pattern | JTO Clinical and Research Reports | 2022 | 12 |
| 24 | Real-World Scenario of Patients With Lung Cancer Amid the Coronavirus Disease 2019 Pandemic in the People’s Republic of China | JTO Clinical and Research Reports | 2020 | 11 |
| 25 | Blood-Based Surveillance Monitoring of Circulating Tumor DNA From Patients With SCLC Detects Disease Relapse and Predicts Death in Patients With Limited-Stage Disease | JTO Clinical and Research Reports | 2020 | 11 |
| 26 | Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report | JTO Clinical and Research Reports | 2020 | 11 |
| 27 | Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study | JTO Clinical and Research Reports | 2021 | 11 |
| 28 | Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Kras Mutation in East Asian Populations: A Single-Center Cohort Study in Taiwan | JTO Clinical and Research Reports | 2021 | 11 |
| 29 | Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers | JTO Clinical and Research Reports | 2021 | 11 |
| 30 | Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer | JTO Clinical and Research Reports | 2020 | 11 |
| 31 | Real-World Survival Outcomes Based on EGFR Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study | JTO Clinical and Research Reports | 2022 | 11 |
| 32 | Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIR02-Lung Trial | JTO Clinical and Research Reports | 2020 | 10 |
| 33 | Utility of Newly Proposed Grading System From International Association for the Study of Lung Cancer for Invasive Lung Adenocarcinoma | JTO Clinical and Research Reports | 2021 | 10 |
| 34 | Abemaciclib in Combination With Pembrolizumab for Stage IV KRAS-Mutant or Squamous NSCLC: A Phase 1b Study | JTO Clinical and Research Reports | 2021 | 10 |
| 35 | Medicolegal Considerations in Multidisciplinary Cancer Care | JTO Clinical and Research Reports | 2020 | 10 |
| 36 | Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC | JTO Clinical and Research Reports | 2020 | 10 |
| 37 | High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience | JTO Clinical and Research Reports | 2022 | 10 |
| 38 | Biomarker Testing for Patients With Advanced/Metastatic Nonsquamous NSCLC in the United States of America, 2015 to 2021 | JTO Clinical and Research Reports | 2022 | 10 |
| 39 | A Catalog of 5’ Fusion Partners in ROS1-Positive NSCLC Circa 2020 | JTO Clinical and Research Reports | 2020 | 9 |
| 40 | Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes | JTO Clinical and Research Reports | 2020 | 9 |
| 41 | Clinical Efficacy and Safety of Nivolumab in Japanese Patients With Malignant Pleural Mesothelioma: 3-Year Results of the MERIT Study | JTO Clinical and Research Reports | 2021 | 9 |
| 42 | Brief Report: Risk Prediction Model Versus United States Preventive Services Task Force 2020 Draft Lung Cancer Screening Eligibility Criteria—Reducing Race Disparities | JTO Clinical and Research Reports | 2021 | 9 |
| 43 | Clinical Characteristics and Outcomes in Advanced KRAS-Mutated NSCLC: A Multicenter Collaboration in Asia (ATORG-005) | JTO Clinical and Research Reports | 2022 | 9 |
| 44 | Sex Differences in Lung Cancer Treatment and Outcomes at a Large Hybrid Academic-Community Practice | JTO Clinical and Research Reports | 2022 | 9 |
| 45 | A Phase II Study of the Multikinase Inhibitor Ponatinib in Patients With Advanced, RET-Rearranged NSCLC | JTO Clinical and Research Reports | 2020 | 8 |
| 46 | Patients With BRAF-Mutant NSCLC May Not Benefit From Immune Checkpoint Inhibitors: A Population-Based Study | JTO Clinical and Research Reports | 2020 | 8 |
| 47 | JNJ-64041757 (JNJ-757), a Live, Attenuated, Double-Deleted Listeria monocytogenes–Based Immunotherapy in Patients With NSCLC: Results From Two Phase 1 Studies | JTO Clinical and Research Reports | 2021 | 8 |
| 48 | Racial and Other Healthcare Disparities in Patients With Extensive-Stage SCLC | JTO Clinical and Research Reports | 2021 | 8 |
| 49 | Correlating ROS1 Protein Expression With ROS1 Fusions, Amplifications, and Mutations | JTO Clinical and Research Reports | 2021 | 8 |
| 50 | Biomarker Testing for People With Advanced Lung Cancer in England | JTO Clinical and Research Reports | 2021 | 8 |
